Please assess the completion status of the following clinical trial:

Trial Title: Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gave an informed consent~* Forced expiratory volume in 1 second \< 80% predicted~* Forced expiratory volume in 1 second / Forced vital capacity \< 70%~* No exacerbation in the last 4 weeks~* Current or ex-smoker~* Smoking history of at least 10 pack/year~* Body mass index of at least 25 kg/m2~* Waist circumference of at least 94 cm~* Fasting blood triglycerides of at least 1.7 mmol/L~Exclusion Criteria:~* Any significant pulmonary pathology other than COPD~* Under oxygen therapy more than 12 hours per day~* More than 2 exacerbation episodes in the last 12 months~* The patient is currently participating to the active phase of a rehabilitation program~* Patient has been under roflumilast therapy prior to enrollment~* Unstable hypertriglyceridemia or hypercholesterolemia~* Under diabetes therapy (hypoglycemic agent or insulin)~* Cancer history in the last 5 years (except basal cell carcinoma)~* Moderate or severe hepatic impairment~* Used prednisone or systemic corticosteroids in the last 4 weeks

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: EXPERIMENTAL): Roflumilast 500 mcg, once daily for 6 months
- Placebo pill (Type: PLACEBO_COMPARATOR): Placebo pill, once daily for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).